Biotech firm PsiOxus Therapeutics, based at Milton Park, has launched the first clinical trial of its new anti-cancer vaccine, ColoAd1.
ColoAd1 is capable of destroying tumour cells at minute concentrations and can be injected into the bloodstream where it kills cancer cells while ignoring normal cells.
Chief executive John Beadle said: “This study could forge a path to a new treatment option for patients with metastatic cancer.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article